Interim clinical commissioning policy: Remdesivir and molnupiravir for non-hospitalised patients with COVID-19

Document first published:
Page updated:
Topic:
,
Publication type:

This policy specifically outlines the treatment options for remdesivir and molnupiravir in non-hospitalised adults and children aged 12 years and older with COVID-19 who are symptomatic and showing no evidence of clinical recovery in accordance with the criteria set out in this document. The options are:

  • First-line: nirmatrelvir plus ritonavir (as per the published NICE MTA)
  • Second-line: sotrovimab (as per the published NICE MTA)
  • Third-line: remdesivir (where supply is available)
  • Fourth-line: molnupiravir

Document

Interim Clinical Commissioning Policy: Remdesivir and molnupiravir for non-hospitalised patients with COVID-19

Interim Clinical Commissioning Policy: Remdesivir and molnupiravir for non-hospitalised patients with COVID-19

  • PDF
  • 521 KB
  • 7 pages

Summary

Published 11 May 2023.